share_log

和黄医药:沃瑞沙 (赛沃替尼) 获国家药监局常规批准用于治疗局部晚期或转移性MET外显子14非小细胞肺癌

Hutchmed (China): Savolitinib (ORPATHYS) has received regular approval from the National Medical Products Administration for the treatment of locally advanced or metastatic non-small cell lung cancer with MET exon 14 mutations.

Breakings ·  Jan 14 06:25

On January 14, Hutchmed (China) Limited announced that the application for new indications of Savolitinib (ORPATHYS, savolitinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer carrying MET exon 14 mutations has been approved by the National Medical Products Administration of China. The administration has also transitioned the previously conditional approval for Savolitinib in treated patients to a regular approval. The new indications for Savolitinib in China will expand to cover both treatment-naïve and treated patients.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment

    Statement

    This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.